ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 591,52
0,60%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. CytomX Therapeutics Inc (CTMX)

  7. CytomX Therapeutics Inc (CTMX) Actualités

CTMX CytomX Therapeutics Inc

1,3808
-0,0792 (-5,42%)
15 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
CytomX Therapeutics Inc CTMX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,0792 -5,42% 1,3808 06:00:04
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,45 1,375 1,485 1,38 1,46
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
14/6/202422:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/5/202422:05GLOBECytomX Therapeutics to Present at the Jefferies Global..
17/5/202423:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202423:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202423:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202423:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202423:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202422:01EDGAR2Form 8-K - Current report
16/5/202422:15GLOBECytomX Therapeutics Announces New Employment Inducement..
13/5/202422:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/5/202422:41EDGAR2Form 8-K - Current report
08/5/202422:10GLOBECytomX Therapeutics Reports First Quarter 2024 Financial..
08/5/202422:04EDGAR2Form 8-K - Current report
08/5/202422:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202422:15GLOBECytomX Therapeutics Announces Clinical Collaboration with..
01/5/202414:00GLOBECytomX Therapeutics to Report First Quarter 2024 Results and..
08/4/202414:00GLOBECytomX Therapeutics Announces First Patient Dosed with..
03/4/202414:00GLOBECytomX Therapeutics Announces Nomination of Second Clinical..
21/3/202413:00GLOBECytomX Therapeutics Appoints Dr. Zhen Su to Board of..
18/3/202413:00GLOBECytomX Therapeutics Announces Milestone Achievement in..
11/3/202421:30EDGAR2Form S-8 - Securities to be offered to employees in employee..
11/3/202421:10GLOBECytomX Therapeutics Reports 2023 Financial Results and..
11/3/202421:02EDGAR2Form 8-K - Current report
11/3/202421:00EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
11/3/202411:39IHMARKETNEWSU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s..
04/3/202414:00GLOBECytomX Therapeutics to Report Fourth Quarter and Full Year..
27/2/202414:00GLOBECytomX Therapeutics to Present at Upcoming March Investor..
24/1/202414:00GLOBECytomX Therapeutics Announces FDA Clearance of IND..
20/1/202402:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/1/202402:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/1/202402:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/1/202402:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/1/202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/1/202414:00GLOBECytomX Therapeutics to Present at the B. Riley Securities..
04/1/202414:00GLOBECytomX Therapeutics Outlines 2024 Company Priorities and..
22/12/202322:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202322:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202322:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202314:00GLOBECytomX Therapeutics to Present at the 42nd Annual J.P...
20/12/202301:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202301:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202301:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202301:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/11/202322:15GLOBECytomX Therapeutics Reports Third Quarter 2023 Financial..
07/11/202322:05EDGAR2Form 8-K - Current report
07/11/202322:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202313:00GLOBECytomX Therapeutics to Present at Upcoming November Investor..
31/10/202313:00GLOBECytomX Therapeutics to Report Third Quarter 2023 Financial..
30/10/202313:00GLOBECytomX Therapeutics to Present Preclinical Data for..

Dernières Valeurs Consultées

NASDAQ
CTMX
CytomX Therapeutics
LSE
BW50
City Gotebg 29
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés